Avadel Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Avadel Pharmaceuticals's earnings have been declining at an average annual rate of -25.8%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been declining at an average rate of 63.7% per year.
Key information
-25.8%
Earnings growth rate
-7.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -63.7% |
| Return on equity | -182.7% |
| Net Margin | -573.2% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16
Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years
Jan 10Avadel files US application for its lead drug
Dec 16Avadel's Xyrem Competitor: A Quick Overview
Dec 15Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Dec 15Revenue & Expenses BreakdownBeta
How Avadel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 28 | -160 | 152 | 13 |
| 30 Sep 23 | 9 | -159 | 127 | 17 |
| 30 Jun 23 | 1 | -143 | 102 | 17 |
| 31 Mar 23 | 0 | -142 | 77 | 18 |
| 31 Dec 22 | 0 | -137 | 75 | 21 |
| 30 Sep 22 | 0 | -132 | 79 | 17 |
| 30 Jun 22 | 0 | -134 | 86 | 18 |
| 31 Mar 22 | 0 | -90 | 79 | 20 |
| 31 Dec 21 | 0 | -77 | 68 | 17 |
| 30 Sep 21 | 0 | -66 | 56 | 20 |
| 30 Jun 21 | 0 | -56 | 44 | 21 |
| 31 Mar 21 | 10 | -6 | 36 | 19 |
| 31 Dec 20 | 22 | 7 | 32 | 20 |
| 30 Sep 20 | 33 | 16 | 31 | 23 |
| 30 Jun 20 | 48 | 18 | 28 | 25 |
| 31 Mar 20 | 55 | -21 | 28 | 31 |
| 31 Dec 19 | 59 | -33 | 30 | 33 |
| 30 Sep 19 | 69 | -94 | 46 | 31 |
| 30 Jun 19 | 75 | -101 | 65 | 35 |
| 31 Mar 19 | 86 | -96 | 86 | 37 |
| 31 Dec 18 | 103 | -95 | 100 | 39 |
| 30 Sep 18 | 117 | -40 | 101 | 66 |
| 30 Jun 18 | 137 | -2 | 88 | 54 |
| 31 Mar 18 | 154 | 30 | 73 | 42 |
| 31 Dec 17 | 173 | 68 | 59 | 33 |
| 30 Sep 17 | 182 | 81 | 46 | 0 |
| 30 Jun 17 | 174 | 40 | 48 | 0 |
| 31 Mar 17 | 167 | -9 | 47 | 0 |
| 31 Dec 16 | 150 | -41 | 45 | 34 |
| 30 Sep 16 | 152 | 28 | 40 | 0 |
| 30 Jun 16 | 167 | 19 | 32 | 0 |
| 31 Mar 16 | 177 | 23 | 27 | 0 |
| 31 Dec 15 | 173 | 42 | 22 | 0 |
| 30 Sep 15 | 127 | -64 | 19 | 0 |
| 30 Jun 15 | 87 | -46 | 18 | 0 |
| 31 Mar 15 | 43 | -49 | 17 | 0 |
| 31 Dec 14 | 15 | -89 | 16 | 0 |
| 30 Sep 14 | 4 | -56 | 17 | 0 |
| 30 Jun 14 | 2 | -52 | 16 | 0 |
| 31 Mar 14 | 4 | -65 | 14 | 0 |
| 31 Dec 13 | 4 | -47 | 13 | 0 |
| 30 Sep 13 | 24 | -39 | 10 | 0 |
| 30 Jun 13 | 23 | -39 | 11 | 0 |
Quality Earnings: AVDL is currently unprofitable.
Growing Profit Margin: AVDL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVDL is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare AVDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: AVDL has a negative Return on Equity (-182.67%), as it is currently unprofitable.